EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027

EBMT Acute Leukaemia ALWP

EBMT Chronic Malignancies CMWP

Thursday, 21 January 2027

09:00 – 13:00	**Scientific Business Meetings**	
14:00 – 16:00	**Session I: Novel insights on allo-HCT indications and management** **Chairs:** *Giorgia Battipaglia (IT) & Joanna Drozd-Sokołowska (PL)*	
14:00 – 14:15	Welcome and Introduction	Marie Robin (FR) Eolia Brissot (FR)
14:15 – 14:35	Allo-HCT Recommendation in Non-Classical MPN and MDS/MPN	Nicola Polverelli (IT)
14:35 – 14:55	Defining Remission and Relapse in MDS/MPN Overlaps	Donal McLornan (UK)
14:55 – 15:15	Update on Allo-HCT Indications in AML	Jordi Esteve (ES)
15:15 – 15:35	Update on Allo-HCT for ALL in CR1	Sebastian Giebel (PL)
15:35 – 15:45	*Oral Presentation*: An unusual case of multiply relapsed acute promyelocytic leukaemia	Carlangela Causa (IT)
15:45 – 15:55	*Oral Presentation*: Novel Insights into Allo-HCT Indications and Long-Term Management in an Older Patient with High-Risk Systemic Mastocytosis Associated with CMML and Severe Hepatic Infiltration	Covadonga Lomo Martínez (ES)
15:55 – 16:00	Discussion	
16:00 – 16:30	**Coffee Break**	
16:30 – 17:15	**Industry Symposium Slot**	
17:15 – 18:45	**Session II: Session II: Allo-HCT in high-risk AML or MDS** **Chairs:** *Kavita Raj (UK) & Fabio Ciceri (IT) & Angeliki Georgopoulou (GR)*	
17:15 – 17:35	Role of Allo-HCT in High-Risk AML	Annalisa Ruggeri (IT)
17:35 – 17:55	Upfront versus Cytoreduction before Transplant in MDS	Marie Robin (FR)
17:55 – 18:15	Maintenance Post Allo in AML	Jaime Sanz (ES)
18:15 – 18:25	*Oral Presentation*: Allogeneic stem cell transplantation in relapsed/refractory acute myeloid leukaemia with active disease: the role of prophylactic post-transplant strategies to enhance Graft versus Leukaemia effect	Federica Frenza (IT)
18:25 – 18:35	*Oral Presentation*: Acquired ETV6::ABL1 Fusion during Clonal Evolution of NPM1-Mutated FLT3-ITD Acute Myeloid Leukaemia	Manuel Alegre Antelo (ES)
18:35 – 18:45	Discussion	

For further information, please get in contact with education.events@ebmt.org

EBMT Transplantation and Cellular Therapy in Myeloid Malignancies Meeting

Paris, France | 21-22 January 2027

EBMT Acute Leukaemia ALWP

EBMT Chronic Malignancies CMWP

Friday, 22 January 2027

09:00 – 10:30	**Session III: CAR-T Cell Therapy for ALL and AML/MDS: Where Do We Stand?**	
	Chairs: *Arnon Nagler (IL) & Guillermo Orti (ES)*	
09:00 – 09:20	Up to Date on CAR-T Therapy for AML and High-Risk MDS	Joanna Drozd-Sokołowska (PL)
09:20 – 09:40	Calreticulin-Targeted CAR T-cell Therapy in MPN	Alex Rampotas (UK)
09:40 – 10:00	Update CAR-T in ALL	Eolia Brissot (FR)
10:00 – 10:10	*Oral Presentation*: Paraneoplastic Spondyloarthritis-like Syndrome Tracking Leukemic Burden in Early-Relapsed, Refractory Acute Myeloid Leukaemia	Abdul Walli Cana (PH)
10:10 – 10:30	Discussion	
10:30 – 11:30	**Keynote Lecture**	
	Chair: *Marie Robin (FR)*	
10:30 – 11:15	Innovative therapies in myelofibrosis	Jean-Jacques Kiladjian (FR)
11:15 – 11:30	Q&A	
11:30 – 12:00	**Coffee Break**	
12:00 – 12:45	**Industry Symposium Slot**	
12:45 – 14:15	**Session IV: Post Allo-HCT Management in BCR::ABL1 mutated leukaemias**	
	Chairs: *Gesine Bug (DE) & Yves Chalandon (CH)*	
12:45 – 13:05	EBMT-Lead Expert Recommendation on CML Management Post Allo-HCT	Hugues de Lavallade (UK)
13:05 – 13:25	Optimizing Management of Ph+ ALL after Transplant and CAR-T Cells	Gesine Bug (DE)
13:25 – 13:45	How to Assess Quality of Life After Transplantation	Chiara Giacon (IT)
13:45 – 13:55	*Oral Presentation*: Isolated central nervous system blast crisis in chronic Myeloid leukaemia: diagnosis despite a normal marrow and salvage with allogeneic transplantation	İbrahim Beyhan (TR)
13:55 – 14:15	Discussion	
14:15 – 14:45	**Coffee Break**	
14:45 – 16:45	**Session V: Controversies**	
	Chairs: *Iman Abou Dalle (LB) & Christoph Scheid (DE)*	
14:45 – 15:35	Is It Time for PTCy to Replace ATG as the Standard GVHD Prophylaxis in Myeloid Malignancies?	
14:45 – 15:05	Yes	Patricia Chiusolo (IT)
15:05 – 15:25	No	Giorgia Battipaglia (IT)
15:25 – 15:35	Q&A	All
15:35 – 16:30	Second Transplantation or DLI in Patients with MDS or AML Relapsing after Transplantation?	
15:35 – 15:45	*Oral Presentation*: Isolated CNS relapse of AML shortly after Haploidentical Allogeneic HSCT in Systemic Mastocytosis with Associated Myeloid Neoplasm	Ana Mellado (ES)
15:45 – 16:05	Second allo	Giuliano Filippini (DE)
16:05 – 16:25	DLI	Christoph Schmid (DE)
16:25 – 16:35	Q&A	All
16:35 – 16:45	Take Home Messages & Closing Remarks	Marie Robin (FR) Eolia Brissot (FR)

For further information, please get in contact with education.events@ebmt.org